Bivalirudin, abciximab and clopidogrel in modern PCI: interpretation and experience from King’s College Hospital

March 2006    Volume 13, Issue 1   Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 5–AIC 8

Authors:
Nick West

Platelet inhibition is a prerequisite for successful percutaneous coronary interventions (PCI). Aspirin was the first antiplatelet agent with proven benefit in ST-elevation infarction (STEMI) in the era of thrombolysis, significantly lowering death rate and the recurrence of ischaemic events.

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top